Mark Chin - Net Worth and Insider Trading
Mark Chin Net Worth
The estimated net worth of Mark Chin is at least $21 Million dollars as of 2024-11-13. Mark Chin is the Director of Imara Inc and owns about 2,344,072 shares of Imara Inc (IMRA) stock worth over $15 Million. Mark Chin is the Director, 10% Owner of Harpoon Therapeutics Inc and owns about 257,236 shares of Harpoon Therapeutics Inc (HARP) stock worth over $6 Million. Mark Chin is also the Director of Iterum Therapeutics PLC and owns about 72,660 shares of Iterum Therapeutics PLC (ITRM) stock worth over $107,537. Besides these, Mark Chin also holds Pyxis Oncology Inc (PYXS) . Details can be seen in Mark Chin's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mark Chin has not made any transactions after 2022-04-21 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Mark Chin
Mark Chin Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark Chin owns 6 companies in total, including Iterum Therapeutics PLC (ITRM) , Harpoon Therapeutics Inc (HARP) , and Imara Inc (IMRA) among others .
Click here to see the complete history of Mark Chin’s form 4 insider trades.
Insider Ownership Summary of Mark Chin
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ITRM | Iterum Therapeutics PLC | 2019-05-24 | director |
| HARP | Harpoon Therapeutics Inc | 2019-12-17 | director & 10 percent owner |
| IMRA | Imara Inc | 2021-07-16 | director & 10 percent owner |
 | | 2022-04-21 | other: Former Director |
| | 2022-12-29 | director |
| | 2020-03-11 | director & 10 percent owner |
Mark Chin Latest Holdings Summary
Mark Chin currently owns a total of 4 stocks. Among these stocks, Mark Chin owns 2,344,072 shares of Imara Inc (IMRA) as of July 16, 2021, with a value of $15 Million and a weighting of 71.08%. Mark Chin owns 257,236 shares of Harpoon Therapeutics Inc (HARP) as of December 17, 2019, with a value of $6 Million and a weighting of 28.4%. Mark Chin also owns 72,660 shares of Iterum Therapeutics PLC (ITRM) as of October 30, 2018, with a value of $107,537 and a weighting of 0.52%. The other 1 stocks Pyxis Oncology Inc (PYXS) have a combined weighting of 0% among all his current holdings.
Latest Holdings of Mark Chin
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| IMRA | Imara Inc | 2021-07-16 | 2,344,072 | 6.32 | 14,814,535 |
| HARP | Harpoon Therapeutics Inc | 2019-12-17 | 257,236 | 23.01 | 5,919,000 |
| ITRM | Iterum Therapeutics PLC | 2018-10-30 | 72,660 | 1.48 | 107,537 |
| PYXS | Pyxis Oncology Inc | 2022-04-21 | 0 | 4.62 | 0 |
Holding Weightings of Mark Chin
Mark Chin Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark Chin has made a total of 2 transactions in Imara Inc (IMRA) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Imara Inc is the acquisition of 1,333,333 shares on July 16, 2021, which cost Mark Chin around $8 Million.
According to the SEC Form 4 filings, Mark Chin has made a total of 2 transactions in Harpoon Therapeutics Inc (HARP) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Harpoon Therapeutics Inc is the sale of 3,656 shares on December 17, 2019, which brought Mark Chin around $621,852.
According to the SEC Form 4 filings, Mark Chin has made a total of 0 transactions in Iterum Therapeutics PLC (ITRM) over the past 5 years. The most-recent trade in Iterum Therapeutics PLC is the acquisition of 3,867 shares on October 30, 2018, which cost Mark Chin around $353,800.
More details on Mark Chin's insider transactions can be found in the Insider Trading History of Mark Chin table.Insider Trading History of Mark Chin
- 1
Mark Chin Trading Performance
GuruFocus tracks the stock performance after each of Mark Chin's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Chin is 9.99%. GuruFocus also compares Mark Chin's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Chin within 3 months outperforms 2 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark Chin's insider trading performs compared to the benchmark.
Performance of Mark Chin
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -8.46 | | | | | |
| Relative Return to S&P 500(%) | -13.85 | | | | | |
Mark Chin Ownership Network
Ownership Network List of Mark Chin
Ownership Network Relation of Mark Chin
Mark Chin Owned Company Details
What does Iterum Therapeutics PLC do?
Who are the key executives at Iterum Therapeutics PLC?
Mark Chin is the director of Iterum Therapeutics PLC. Other key executives at Iterum Therapeutics PLC include Chief Scientific Officer Michael W. Dunne , director & President & CEO Fishman Corey N. , and Chief Medical Officer Sailaja Puttagunta .
Iterum Therapeutics PLC (ITRM) Insider Trades Summary
Over the past 18 months, Mark Chin made no insider transaction in Iterum Therapeutics PLC (ITRM). Other recent insider transactions involving Iterum Therapeutics PLC (ITRM) include a net purchase of 55,000 shares made by Michael W. Dunne , and a net purchase of 10,000 shares made by Fishman Corey N. .
In summary, during the past 3 months, insiders sold 0 shares of Iterum Therapeutics PLC (ITRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Iterum Therapeutics PLC (ITRM) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 65,000 shares.
Iterum Therapeutics PLC (ITRM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Iterum Therapeutics PLC Insider Transactions
Mark Chin Mailing Address
Above is the net worth, insider trading, and ownership report for Mark Chin. You might contact Mark Chin via mailing address: 20 Berkeley Square, Mayfair, London X0 W1j 6eq.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
